Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Download PDF Copy

Dec 11 2009

NewsGuard 100/100 Score

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

These data showed that women who switched to Aromasin® (exemestane tablets) after 2.5 years of tamoxifen experienced a 19 percent reduction in risk of breast cancer recurrence (BCFS)>

Source:

Pfizer

Posted in: Drug Trial News | Medical Condition News

Tags: Adjuvant Therapy, Aromatase Inhibitor, Arthralgia, Bone, Breast Cancer, Cancer, Creatinine, Endoplasmic reticulum (ER), Estrogen, Hormone, Hypersensitivity, Melanoma, Nursing, Oncology, Osteoporosis, Receptor, Tamoxifen, Thrombosis

Comments (0)

Download PDF Copy

Suggested Reading

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Researchers uncover key genes linked to DCIS progression

Researchers uncover key genes linked to DCIS progression

AI-powered tool predicts gene activity in cancer cells from biopsy images

AI-powered tool predicts gene activity in cancer cells from biopsy images

Study shows AI can predict prognosis in triple-negative breast cancer

Study shows AI can predict prognosis in triple-negative breast cancer

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Study shows cannabis as a genotoxic substance with cancer risks

Study shows cannabis as a genotoxic substance with cancer risks

How different types of bread impact cancer risk

How different types of bread impact cancer risk

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New vaccine shows potential in preventing recurrence of triple-negative breast cancer